LISINOPRIL TABLETS
Country: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
18-08-2009
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
LISINOPRIL (LISINOPRIL DIHYDRATE)
Fáanlegur frá:
RANBAXY PHARMACEUTICALS CANADA INC.
ATC númer:
C09AA03
INN (Alþjóðlegt nafn):
LISINOPRIL
Skammtar:
20MG
Lyfjaform:
TABLET
Samsetning:
LISINOPRIL (LISINOPRIL DIHYDRATE) 20MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
100
Gerð lyfseðils:
Prescription
Lækningarsvæði:
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Vörulýsing:
Active ingredient group (AIG) number: 0121550002; AHFS:
Leyfisstaða:
APPROVED
Leyfisdagur:
2009-08-20
Vara einkenni
_ _
_Page 1 of 41_
PRODUCT MONOGRAPH
PR
LISINOPRIL TABLETS
(LISINOPRIL)
5 mg, 10 mg and 20 mg of lisinopril as lisinopril dihydrate
USP
Angiotensin Converting Enzyme Inhibitor
Ranbaxy Pharmaceuticals Canada Inc.
2680 Matheson Blvd East, Suite 200
Mississauga, Ontario
L4W 0A5
Date of Preparation:
August 17, 2009
Submission Control No: 131981
_ _
_ _
_Page 2 of 41_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL
USE.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND
PRECAUTIONS.................................................................................
4
ADVERSE
REACTIONS.................................................................................................
10
DRUG INTERACTIONS
.................................................................................................
16
DOSAGE AND
ADMINISTRATION.............................................................................
18
OVERDOSAGE
...............................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 21
STORAGE AND
STABILITY.........................................................................................
24
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 24
PART II: SCIENTIFIC INFORMATION
..............................................................................
25
PHARMACEUTICAL
INFORMATION.........................................................................
25
CLINICAL
TRIALS.........................................................................................................
26
DETAILED
PHARMACOLOGY
Lestu allt skjalið
